四環醫藥(00460.HK)：獨家代理的玻尿酸鉑安潤®獲批
格隆匯4月18日丨四環醫藥(00460.HK)宣佈，由集團獨家代理並由韓國Hugel Inc.(”Hugel“)生產的注射用修飾透明質酸鈉凝膠(商品名：鉑安潤®，Persnica™)(”玻尿酸鉑安潤®“或”該產品“)於2022年4月正式獲得國家藥監局頒發的三類醫療器械註冊證。
玻尿酸鉑安潤®是一種無菌、無熱原、非動物源性交聯透明質酸鈉凝膠，適用於面部真皮組織中層注射糾正中重度鼻脣溝皺紋。該產品採用單相交聯技術製成，具有支撐力好、不擴散移位、代謝勻速、塑型持久、黏性值高、交聯度高、塑形能力強等優點。玻尿酸鉑安潤®在BDDE的處理上也更加安全，在使用較少BDDE的情況下交聯程度達到最高，使產品塑形能力效果更強，並且注射時柔和，注射後無異物感，塑形更加自然。同時，BDDE在生產過程中通過多次長時間滲析工藝被完全去除，保證產品完全安全，不會因此產生任何過敏和副作用。
玻尿酸鉑安潤®屬於Hugel旗下的Across生產的透明質酸產品，該產品配方更適合亞洲人體質及審美需求，是韓國最受歡迎的透明質酸填充劑品牌之一，深受年輕人的喜愛和追捧。該產品已獲得韓國食品藥品監督管理局認證，並獲得CE認證，已出口到歐洲和世界各地。
根據新氧數據，截至2021年，中國醫美產業規模預計將達到約人民幣1,846億元，同比增長21.6%，醫美用户規模達到1,813萬人，同比增長19.27%，相比2017年複合年均增速(”CAGR“)為45.91%，預計2022年，醫美用户將達到2,093萬人。根據Frost&Sullivan數據，2019年中國醫美注射劑行業市場規模為人民幣71.1億元，其中透明質酸佔比66.6%。2020年基於透明質酸的皮膚填充劑市場規模達人民幣49億元，2016–2020年CAGR為18.9%，預計將於2023年突破人民幣百億規模，2025年達到人民幣157億元，2020–2025年CAGR為26.3%，保持高速增長趨勢。
該次四環醫藥獨家代理的玻尿酸鉑安潤®獲批不僅豐富了集團的產品矩陣，且在該產品上市後可藉助肉毒毒素產品樂提葆®已建立起來的市場基礎及品牌影響力，快速拓展和滲透透明質酸填充劑市場，為求美者提供適合體質的高品質及高性價比產品。另外，玻尿酸鉑安潤®可以與樂提葆®聯合應用，達到1+1大於2的效果。臨牀效果顯示，玻尿酸鉑安潤®與肉毒毒素樂提葆®聯合使用，可以增加透明質酸在人體裏的停留時間，令肌肉減少對透明質酸的擠壓，使美容塑型的效果更加持久。同時，使用樂提葆®後的肌肉放鬆時形態穩定，塑形效果更好。透明質酸和肉毒毒素均是市場上高價值產品，該次玻尿酸鉑安潤®進入集團的醫療美容平台，不僅豐富和擴大了平台的產品組合，還體現了集團的產品佈局策略面向多元化與國際化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
